Key Takeaways
- A surgical robot is a surgeon-controlled instrument system, not an autonomous operator. The surgeon remains responsible for every movement and decision [1].
- “Robotic surgery” is not one treatment. Evidence from prostate, rectal, cardiac, gynaecologic, thoracic, orthopaedic or neurosurgical procedures cannot be pooled into a universal promise.
- The useful comparison is the same operation for the same indication: robotic versus conventional laparoscopy or open surgery, with outcomes that matter to that patient.
- Surgeon experience should be measured in recent cases of the proposed procedure and platform—not total career operations or the hospital’s cumulative robot count.
- A safe programme needs an experienced bedside assistant, anaesthesia and nursing team, working backup equipment and a rehearsed plan for undocking and conversion.
Content
The word “robot” can make a familiar operation sound like a completely different treatment. In practice, the diagnosis and surgical objective come first. A prostate still has to be removed with appropriate margins; a rectal tumour still has to be dissected safely; a joint replacement still has to be planned and implanted. The platform changes how the surgeon sees, reaches or guides instruments. It does not make the indication correct, erase difficult anatomy or guarantee a better result.
The US FDA describes computer-assisted surgical systems as devices through which the surgeon directly controls instruments from a console. Current systems do not perform surgery on their own [1]. This distinction matters when a hospital advertises “AI surgery,” “intelligent surgery” or “one-click precision.” Ask what the software actually does: camera control, navigation, image registration, trajectory planning, instrument movement or something else.
First identify the operation—not just the platform
Before comparing routes, write one clear sentence:
The proposed operation is for disease, using access, with as the main clinical goal.
Then record the alternatives. For an abdominal or pelvic operation they may include open surgery, conventional laparoscopy and robot-assisted laparoscopy. For an orthopaedic procedure, the system may guide alignment or bone preparation rather than move wristed instruments inside a body cavity. Neurosurgical and spinal systems may provide navigation or trajectory assistance. Those categories solve different technical problems and should not borrow one another’s evidence.
The model and version also matter. A multi-port soft-tissue platform, a single-port system and an orthopaedic robotic arm have different instruments, approved uses, failure modes and training requirements. Confirm the exact registered device and intended use in the hospital’s documents; do not infer them from a brand logo in promotional material.
Where the technology may help
Depending on the platform and procedure, useful features may include:
- a magnified three-dimensional operative view;
- articulated instruments that work at angles difficult for straight laparoscopic tools;
- motion scaling and filtering of small hand tremor;
- stable camera control under the operating surgeon;
- navigation or planning that links imaging to an operative target;
- improved surgeon ergonomics during a long case.
These are technical advantages. A technical advantage becomes a patient benefit only if it changes a meaningful outcome: fewer complications, less blood loss or pain, shorter recovery, better function, better cancer control, fewer conversions or a more reliable implant position. Even then, the size of benefit may be modest and procedure-specific.
What the system cannot remove
Robotic access does not cancel the risks of the operation itself. Bleeding, infection, anaesthetic complications, organ or nerve injury, thrombosis, leakage, urinary or sexual dysfunction, incomplete tumour removal and reoperation remain relevant according to the procedure.
The platform can also introduce practical limitations:
- docking and instrument exchange take time, especially early in a team’s learning curve;
- robotic arms or ports can collide, and patient access is more restricted after docking;
- many systems provide limited or no natural tactile feedback, so the surgeon relies heavily on vision and experience;
- equipment, image, instrument or power faults may require rapid troubleshooting or conversion;
- steep positioning and prolonged pneumoperitoneum may affect the lungs, circulation, nerves, eyes or pressure injuries in susceptible patients;
- disposable instruments and operating-room time may add cost;
- a minimally invasive plan can still become conventional laparoscopy or open surgery.
FDA post-market reports include mechanical, instrument and display problems as well as injuries and deaths, although a report alone does not establish that a device caused an event [1]. The sensible response is not fear of every machine; it is a specific failure and rescue plan.
Read evidence by procedure and outcome
Results from one operation should not be used as a slogan for another. Two randomised examples show why.
In the ROLARR trial of rectal cancer surgery, conversion to open surgery occurred in 8.1% of robot-assisted cases and 12.2% of conventional laparoscopic cases, but the difference was not statistically significant. Circumferential margin positivity also did not differ significantly [5]. That trial does not prove that robots never help in rectal surgery. It shows that a plausible technical advantage did not automatically become a clear overall trial advantage.
A more recent randomised trial comparing robot-assisted and open radical prostatectomy found less blood loss and a shorter hospital stay with the robotic route, with some functional recovery advantages. Ninety-day complication rates were not significantly different, and cancer outcomes were comparable at 36 months [6]. This comparison was robotic versus open, not robotic versus conventional laparoscopy, and its findings should not be exported to other cancers.
A systematic review of randomised trials across several operations similarly found that conclusions depend on the procedure and selected endpoint [7]. When a hospital says its outcomes are “better,” ask for the actual denominator, comparator, time point and definition.
The patient’s anatomy still decides much of the plan
Suitability can be affected by tumour size and local invasion, previous operations, adhesions, prior radiotherapy, body habitus, cardiopulmonary reserve, bleeding risk, infection, joint or spine mobility and ability to tolerate the required position. For cancer, neoadjuvant treatment, lymph-node plan, margin strategy and the possibility of removing adjacent organs may matter more than the instrument platform.
A difficult case is not automatically “ideal for a robot.” It may benefit from articulation and visualisation, or it may require faster open access and a different team. The operating surgeon should explain why the proposed route fits this patient rather than citing the robot’s general capabilities.
Ask about the surgeon’s exact experience
“Our centre has done 10,000 robotic procedures” says little about the person performing tomorrow’s operation. Ask the lead surgeon:
- How many of this exact procedure have you performed robotically, and how many in the past 12 months?
- How many were for patients with similar disease stage or complexity?
- Which platform and model were used, and will you be at the console for the key steps?
- Where are you on the learning curve for this operation? Was proctoring required or recently completed?
- What are your conversion, major complication, readmission and reoperation rates, with denominators and follow-up periods?
- For cancer, what are the relevant margin, node-yield, recurrence or functional results?
- Who takes over if the lead surgeon becomes unavailable during the case?
Good surgeons may not have a glossy dashboard, but they should be able to describe their own practice honestly and place it in the context of published evidence. A refusal to define “success” or disclose who performs critical steps is more concerning than the absence of a round marketing number.
Experience belongs to the whole operating room
Once the surgeon is seated at a console, the bedside assistant has immediate access to the patient. That person may exchange instruments, suction, retract, clip, control bleeding, remove specimens and help undock. Anaesthesiologists manage the physiological effects of position and insufflation while access to the airway or patient may be limited. Scrub nurses, circulating nurses, sterile-processing staff and biomedical engineers keep instruments and systems ready.
Ask whether the same core team works together regularly. Confirm that conventional laparoscopic and open instruments are in the room, blood and critical care are available when indicated, and a qualified surgeon can operate at the bedside during an emergency. A new machine in a highly experienced hospital is not the same as an established robotic programme for the proposed operation.
China’s rules focus on institutional and professional responsibility
China’s medical-technology management measures require medical institutions to maintain technology catalogues, surgical grading, professional authorisation, quality control, records and dynamic evaluation [2]. The National Health Commission’s standard for artificial-intelligence-assisted treatment technology sets institutional, departmental, equipment, personnel and quality-management conditions for robot-assisted surgery [3]. Separate surgical grading rules require ongoing assessment of a surgeon’s technical ability, safety, perioperative management and communication [4].
For a patient, the practical questions are:
- Is the hospital authorised and equipped for this technology and operation?
- Is the named surgeon currently authorised for this grade and procedure?
- What training and supervised cases were completed on the exact platform?
- How are complications, conversions, device problems and outcomes reviewed?
Regulatory compliance is a safety floor, not evidence that one hospital or brand produces the best outcome.
Conversion is a safety option, not automatically a failure
Conversion can occur because of bleeding, adhesions, unexpected anatomy, tumour extent, anaesthetic instability, equipment failure or inability to progress safely. The consent discussion should distinguish conversion to conventional laparoscopy from conversion to open surgery.
Ask how the team will undock, how quickly the patient can be accessed, which surgeon will perform the alternative approach and whether required instruments are already sterile and available. Also ask how conversion changes incision size, recovery, hospital stay and cost. A team that converts early for safety may be exercising good judgement; the quality question is whether it recognised the problem and responded effectively.
Compare complete costs
Obtain an itemised estimate for:
- surgeon, anaesthesia and hospital charges;
- robotic platform or service fee;
- disposable and limited-use instruments;
- imaging, navigation, implants or pathology;
- expected operating-room and inpatient time;
- intensive care or higher-dependency care when relevant;
- conversion, transfusion, complication or readmission costs;
- follow-up, rehabilitation and management of catheters, drains or stomas.
A shorter stay may offset part of a higher theatre cost, but that should be shown using the hospital’s own expected pathway. Do not compare only the device surcharge with only the advertised benefit.
Leave with an operation record that another doctor can use
Request the operative note, anaesthesia record, discharge summary, pathology report, implant or device record and complication plan. The operative note should identify the approach, platform/model, ports or access, important findings, major steps, specimens, implants or stapling devices, blood loss, complications and whether conversion occurred. For cancer, preserve the full pathology report and relevant imaging.
If the patient returns home, the local clinician needs ordinary clinical facts—not a certificate saying “successful robotic surgery.” Urgent symptoms such as severe breathing difficulty, chest pain, fainting, heavy bleeding, worsening abdominal pain with fever, sudden weakness or confusion require immediate local assessment.
Medical disclaimer: This guide supports questions and record review; it does not recommend a platform or surgical route. The appropriate operation depends on diagnosis, anatomy, alternatives, surgeon and team capability, and informed consent.
FAQ
Is robotic surgery performed by artificial intelligence?
No. In currently used computer-assisted systems, the surgeon controls the instruments. Software may support imaging, navigation or motion, but it does not replace the surgeon’s clinical judgement or responsibility.
Is robotic surgery always safer than open surgery?
No. Some procedures show advantages in selected outcomes, while other randomised comparisons show little or no significant difference. Safety depends on the exact operation, patient, comparator and team.
How many cases should a robotic surgeon have performed?
There is no universal number for every procedure. Ask for recent experience with the exact operation and platform, stage of the learning curve, supervised training and procedure-specific outcomes.
Does conversion to open surgery mean the operation went wrong?
Not necessarily. Conversion can be the safest response to bleeding, adhesions, unexpected anatomy, disease extent or device problems. The key is whether the team anticipated it and could convert promptly.
What should I compare if robotic surgery costs more?
Compare total expected cost and the outcomes relevant to you: complications, blood loss, pain, hospital stay, functional recovery, cancer control, conversion and possible readmission—not the technology fee alone.
Sources
- US Food and Drug Administration — Robotically Assisted Surgical Devices
- National Health Commission of China — Measures for the Clinical Application Management of Medical Technologies
- National Health Commission of China — Clinical Application Management Standard for Artificial Intelligence-Assisted Treatment Technology (2022)
- National Health Commission of China — Surgical Grading Management Measures (2022)
- JAMA — ROLARR Randomized Clinical Trial of Robotic vs Laparoscopic Rectal Cancer Surgery
- The Lancet Oncology — Randomized Trial of Robot-Assisted vs Open Radical Prostatectomy
- Systematic Review of Randomized Trials of Robotic vs Laparoscopic Surgery
Image Review
- Decision: Replaced with a topic-specific ImageGen hero and visually reviewed for medical relevance, obvious generation artifacts and bilingual reuse.
- Editorial note: The existing image shows a routine clinician–patient consultation and Shanghai skyline but no surgical robot, console, instruments, operating room or procedure comparison. It is visually polished yet materially non-specific. Replace it with a non-branded, anatomically neutral scene showing a surgeon at a console and the bedside team, without implying autonomous surgery.